香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763) 截至2025年6月30日止六個月之中期業績公告 中國同輻股份有限公司（「本公司」或「中國同輻」，連同附屬公司統稱「本集團」或 「我們」）董事（「董事」）會（「董事會」）謹此提呈本集團截至2025年6月30日止六個 月（「2025年上半年」或「報告期」）之未經審核簡明合併財務報表，連同2024年同 期未經審核之比較數字載列如下。 刊登業績公告及中期報告 本公告已於聯交所網站 www.hkexnews.hk 及本公司網站 www.circ.com.cn 發佈。本 公司將於同日在上述網站發佈截至2025年6月30日止六個月的中期報告。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國北京，2025年8月28日 於本公告日期，董事會成員包括執 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發布的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中國同輻股份有限公司於 2025 年 8 月 2 8 日在上海證券交易所網站 ( http://www.sse.com.cn /)刊發的「中國同輻股份有限公司公司債券中期報告（2025 年）」，僅供參閱。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年8月28日 中国同辐股份有限公司 公司债券中期报告 （2025 年） 二〇二五年八月 0 中国同辐股份有限公司公司债券中期报告（2025 年） 重要提示 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁 ...

Core Viewpoint - China Tongdun (01763) reported its mid-year performance for 2025, showing a mixed financial outcome with revenue growth but a decline in profit before tax [1] Financial Performance - The company achieved operating revenue of 831 million, representing a year-on-year increase of 4.24% [1] - The total profit amounted to 171 million, reflecting a year-on-year decrease of 1.93% [1] - The net profit reached 148 million, indicating a year-on-year growth of 4.55% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發佈的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年8月28日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司2025年半年度報告」，僅供 參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年8月28日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及 ...

Major Events - Xianjian Technology (01302) has entered the special review process for innovative medical devices for its nickel-titanium alloy arterial duct occluder [1] - Sunny Optical Technology (02382) signed a memorandum of understanding with GoerTek (002241.SZ) and GoerTek Optical to promote complementary advantages [1] - Fuhong Hanlin (02696) completed the first patient dosing in the U.S. for its HLX43 (targeted PD-L1 antibody conjugate) in an international multi-center Phase II clinical study for advanced non-small cell lung cancer [1] - Shanghai Pharmaceuticals (02607) received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYS 6036 injection in China [1] - Kaisa Group (01638) reached a strategic cooperation with CITIC City Construction for the Shenzhen Futian Jiayuan project [1] - Conant Optical (02276) has been included in the Hang Seng Composite Index [1] - China Railway (00390) is investigating the cause of the Qianzhazhuang Yellow River Bridge accident, which has resulted in 12 fatalities and 4 missing persons [1] - Dongfeng Motor Group (00489) plans to be privatized at a premium, while Lantu Automobile has applied for a listing introduction [1] - Baize Medical (02609) has been included in the Hang Seng Index series [1] - Zhongmiao Holdings (01471) plans to acquire 55% of Beijing Kechuang Rongxin Technology Co., Ltd. for 165 million yuan [1] - Huaxing Capital Holdings (01911) intends to establish a strategic cooperation framework with YZi Labs to support the application of Binance Coin and the BNB Chain ecosystem [1] - Sihuan Pharmaceutical (00460) received approval from the National Medical Products Administration for its self-developed innovative drug, Dirocitin [1] - China Tongru (01763) successfully obtained a radiation safety license for its radiation source R&D and production base [1] Operating Performance - Cathay Pacific (00293) and Hong Kong Express carried approximately 3.2 million passengers in July, setting a new monthly record for the year [2] - CSPC Pharmaceutical Group (01093) reported a mid-year profit attributable to shareholders of 2.548 billion yuan, a decrease of 15.64% year-on-year [2] - TCL Electronics (01070) reported a mid-year net profit of 1.09 billion HKD, an increase of 67.78% year-on-year [2] - Chongqing Bank (01963) reported a mid-year net profit of 3.19 billion yuan, a year-on-year increase of 5.39%, indicating stable profitability [2] - Shenwan Hongyuan Hong Kong (00218) reported a mid-year profit attributable to ordinary shareholders of 60.134 million HKD, turning from loss to profit [2] - Times Electric (03898) reported a mid-year net profit of 1.6715 billion yuan, a year-on-year increase of 12.93% [2] - CIFI Holdings Group (00884) reported mid-year revenue of 12.281 billion yuan, delivering approximately 15,000 property units in the first half of the year [2] - CRRC (01766) reported a mid-year net profit of 7.246 billion yuan, a year-on-year increase of 72.48% [2] - China Tobacco Hong Kong (06055) reported a mid-year profit attributable to shareholders of 706 million HKD, an increase of 9.79% year-on-year [2] - Vanke Enterprises (02202) reported mid-year revenue of 105.323 billion yuan, maintaining operational efficiency among industry peers [2] - Greentown Management Holdings (09979) reported a mid-year profit attributable to shareholders of 256 million yuan [2] Additional Operating Performance - Goldwind Technology (02208) reported a mid-year profit attributable to shareholders of 1.488 billion yuan, an increase of 7.26% year-on-year [3] - Zhouliufu (06168) reported a mid-year net profit of 415 million yuan, an increase of approximately 11.9%, with a mid-year dividend of 0.45 yuan per share [3] - Zhejiang Huhangyong (00576) reported a mid-year profit attributable to shareholders of 2.787 billion yuan, a year-on-year increase of 4% [3] - Dongfeng Motor Group (00489) reported a mid-year profit attributable to shareholders of 55 million yuan, a decrease of 91.96% year-on-year [3] - Zhaojin Mining (01818) reported a mid-year profit attributable to shareholders of approximately 1.44 billion yuan, a year-on-year increase of approximately 160.44% [3]

【今日焦点】 东风集团股份(00489.HK)将分派岚图股份 东风公司拟通过吸收合并方式将公司私有化 25日复牌 东风集团股份(00489.HK)公告，于2025年8月22日，要约人东风汽车集团（武汉）投资有限公司与公司 订立建议交易：(1)分派及介绍上市：公司已决议将其将持有的岚图股份分派予现有股东，且岚图将在 满足分派条件的前提下申请岚图H股介绍上市；及(2)合并：同时，要约人与公司订立合并协议，据其规 定并根据及受限于合并协议的条件及条款（包括合并先决条件及合并条件），要约人与公司同意以现金 对价的方式向所有H股股东（东风公司直接持有的H股除外）实施合并。 待合并先决条件及所有合并生效条件获达成后，公司将向联交所申请自愿撤销H股于联交所的上市地 位。 分派、介绍上市及合并的完成互为先决条件，且分派、介绍上市及合并将在同一天或前后发生。 根据建议交易，H股股东将通过分派及介绍上市，就于分派记录日期持有的每股H股获发0.3552608股岚 图H股。此外，H股股东（东风公司直接持有的H股除外）每股H股将以现金方式收取港币6.68元的注销 价。基于估值顾问按估值参考汇率估算截至2025年7月31日每股岚图H股估 ...

Core Viewpoint - China Tongyuan (01763) has successfully obtained a radiation safety license for its radiation source R&D and production base, marking a significant step in its capability to produce and sell radiation sources [1] Group 1: Project Approval and Capacity - The project is the largest radiation source R&D and production base in Asia, featuring 13 production lines for various radiation sources including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product Offering and Market Impact - The company will consolidate domestic resources for the R&D and production of radiation sources, offering over 70 types of high-quality radionuclide products to both domestic and international markets [1] - Services will include resource recycling and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Expansion Plans - China Tongyuan plans to promote the second phase of the project to further expand production capacity and diversify its product offerings [1] - New production lines for isotopes such as Californium-252, Cesium-137, and Americium-241 are planned to meet diverse market demands [1]

Core Viewpoint - China Tongfu (01763.HK) has successfully obtained a radiation safety license for its subsidiary Sichuan Nuclear Tongyuan Technology Co., Ltd., enabling it to produce and sell radiation sources, marking a significant step in its operational capabilities [1] Group 1: Project Overview - The project is the largest radiation source research and production base in Asia, featuring 13 production lines for various radiation sources including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product and Service Offerings - China Tongfu aims to consolidate domestic resources for the research and production of radiation sources, offering over 70 types of high-quality radionuclide products to both domestic and international markets [1] - The company will provide services for the reuse of radiation source resources and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Expansion Plans - The company plans to promote the second phase of the project with high standards to further expand production capacity and diversify its product offerings [1] - Future production lines will include isotopes such as Californium-252, Cesium-137, and Promethium-241 to meet diverse market demands [1]

Core Viewpoint - China Tongyuan (01763) announced that its subsidiary, Sichuan Nuclear Tongyuan Technology Co., Ltd., has successfully obtained a radiation safety license for its radiation source R&D and production base, marking its official qualification for production and sales of radiation sources [1] Group 1: Project Overview - The project is the largest radiation source R&D and production base in Asia, featuring 13 production lines for various radiation sources, including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product and Service Offerings - China Tongyuan will consolidate domestic resources for R&D and production of radiation sources, offering over 70 types of high-quality radiation source products to both domestic and international markets [1] - The company will provide radiation source resource recycling services and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Plans - The company plans to promote the second phase of the project with high standards to further expand production capacity and diversify its product offerings [1] - Future production lines will include sources such as Californium-252, Cesium-137, and Americium-241 to meet diverse market demands [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願性公告 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 中國同輻放射源研發生產基地成功獲批輻射安全許可證 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣佈，近日，中國同輻旗下附屬公司四川中核同源科技有限公 司的放射源研發生產基地「該項目」成功獲批輻射安全許可證，正式具備放射源生 產、銷售等相關資質，產品將逐步面向市場。 該項目是亞洲最大的放射源研發生產基地，建設包括碳-14源、氪-85源等13條放 射源生產線，該項目建成後年產放射源將超過10萬枚。中國同輻將聚集國內主要 放射源的研發、生產資源，向國內外提供超過70種核素的高質量放射源產品，可 提供放射源資源再利用服務、輻照服務等，為我國工業、農業、 ...